MELA Sciences CEO Michael R. Stewart to Present at the Eighth Annual OneMedForum January 13 at 2 p.m.
January 08 2015 - 6:07PM
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind®
system, a non-invasive software-driven image analysis device
approved for use in the U.S. and the European Union to assist
dermatologists in melanoma diagnosis, today announced that MELA
Sciences' CEO Michael R. Stewart will present at the OneMedForum at
the Marriott Marquis, San Francisco on January 13 at 2:00 p.m. PST.
One-on-one meetings are available through the OneMedConnect
partnering system. Investors who cannot attend the conference can
view the live webcast on OneMedTV.
A replay will be available on the Investor Relations section of
the MELA Sciences home page: at MELA Sciences Investor Relations.
About the OneMedForum
The Annual OneMedForum will host nearly 100 innovative growth
companies from a variety of areas. OneMedForum's
objective is to assemble the most promising companies and
technologies in health and medicine to connect with investors and
executives.
About
MelaFind (www.melafind.com) MelaFind
is the first and only medical device with FDA Pre-Market Approval
(PMA) for the U.S. and Conformité Européenne (CE) Marking
certification for the European Union designed to assist
dermatologists in the evaluation and diagnosis of melanoma at its
most curable and cost-effective stage. The MelaFind system utilizes
innovative software-driven technology and state-of-the-art 3-D
optical imaging to non-invasively extract data 2.5 mm below the
skin surface from patient's pigmented ambiguous moles and
objectively analyzes them with proprietary algorithms. MelaFind
provides important additional perspective to physicians via 3-D
spectral images and 100% objective data analysis to help them
better understand the structural disorganization of a patient's
pigmented ambiguous moles (before cutting the skin) during the
evaluation and diagnosis process for melanoma.
About MELA Sciences, Inc.
(www.melasciences.com) MELA Sciences is a
medical technology company dedicated to designing and developing
innovative software-driven technology for physician clinical use
for the early detection of skin cancer. MELA Sciences conducted the
largest, positive prospective study ever done on the melanoma
disease, and is the first and only medical technology company to
receive both FDA Pre-Market Approval (PMA) for the U.S. and CE
Marking certification for the European Union for their flagship
product MelaFind.
CONTACT: Media
Diana Garcia Redruello
MELA Sciences, Inc.
914-373-6960
Investors
Andrew McDonald
LifeSci Advisors, LLC
646-597-6987
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024